Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Oncogene. 2014 Sep 22;34(29):3770–3779. doi: 10.1038/onc.2014.304

Figure 3. Survivin antagonists inhibit proliferation.

Figure 3

(A-D) Tumor cells were plated on chamber slides and treated for 24 hr with control media (A), 0.1% DMSO (B), 10 μg/ml S12 (C), or 50 nM YM155 (D). Cells were stained with anti-Ki67 antibodies (green) to mark proliferating cells and DAPI (blue) to label cell nuclei. Very few cells were Ki67+ after treatment with Survivin antagonists compared to controls (p<0.0001 for YM155 and S12). Data are representative of 3 experiments. (E-F) Ptch mutant tumor cells were treated with multiple doses of YM155 (E) or S12 (F) for 48 hr and pulsed with 3H-thymidine for 12 hr to measure proliferation. Treatment with either antagonist decreased proliferation in a dose-dependent manner (p< 0.02 for all YM155 and S12 doses except 5μg/ml S12, which was not significant (NS)). Ki67+ percentages in (A) were averaged from 6 images for each treatment. Data in (E-F) represent mean +/- SD and are representative of 6 experiments. Stats were calculated by ANOVA and post hoc student's t-tests.